Carregant...
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC). However, aglycosylated Atezolizumab is unstable...
Guardat en:
| Publicat a: | Sci Rep |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7952408/ https://ncbi.nlm.nih.gov/pubmed/33707569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85329-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|